

  <!doctype html>
<html lang="en-US">

<!-- Mirrored from www.merck.com/news/lynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility/ by HTTrack Website Copier/3.x [XR&CO'2014], Tue, 04 Oct 2022 17:18:34 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1">
    <link rel="profile" href="https://gmpg.org/xfn/11">
    <link rel="preload" as="font" type="font/woff2" href="../../wp-content/themes/mhh-merck-mco-theme/fonts/InventionVF_W_Wght.woff2" crossorigin="anonymous">
<link rel="preload" as="font" type="font/woff2" href="../../wp-content/themes/mhh-merck-mco-theme/fonts/InventionVF_Italics_W_Wght.woff2" crossorigin="anonymous">    <meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' />

	<!-- This site is optimized with the Yoast SEO plugin v18.2 - https://yoast.com/wordpress/plugins/seo/ -->
	<title>LYNK-003 Trial Evaluating LYNPARZA® (olaparib) With or Without Bevacizumab in Patients With Unresectable or Metastatic Colorectal Cancer to Stop for Futility - Merck.com</title>
	<link rel="canonical" href="index.html" />
	<meta property="og:locale" content="en_US" />
	<meta property="og:type" content="article" />
	<meta property="og:title" content="LYNK-003 Trial Evaluating LYNPARZA® (olaparib) With or Without Bevacizumab in Patients With Unresectable or Metastatic Colorectal Cancer to Stop for Futility - Merck.com" />
	<meta property="og:description" content="RAHWAY, N.J., July 18, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, will stop for futility the Phase 3 LYNK-003 trial investigating LYNPARZA with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction. This action follows the [&hellip;]" />
	<meta property="og:url" content="index.html" />
	<meta property="og:site_name" content="Merck.com" />
	<meta property="article:modified_time" content="2022-07-18T20:00:05+00:00" />
	<meta property="og:image" content="../../wp-content/uploads/sites/5/2022/03/Merck.png" />
	<meta property="og:image:width" content="3056" />
	<meta property="og:image:height" content="1380" />
	<meta property="og:image:type" content="image/png" />
	<meta name="twitter:card" content="summary_large_image" />
	<meta name="twitter:label1" content="Est. reading time" />
	<meta name="twitter:data1" content="15 minutes" />
	<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"https://www.merck.com/#website","url":"https://www.merck.com/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.merck.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https://www.merck.com/news/lynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility/#webpage","url":"https://www.merck.com/news/lynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility/","name":"LYNK-003 Trial Evaluating LYNPARZA® (olaparib) With or Without Bevacizumab in Patients With Unresectable or Metastatic Colorectal Cancer to Stop for Futility - Merck.com","isPartOf":{"@id":"https://www.merck.com/#website"},"datePublished":"2022-07-18T20:00:00+00:00","dateModified":"2022-07-18T20:00:05+00:00","breadcrumb":{"@id":"https://www.merck.com/news/lynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.merck.com/news/lynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility/"]}]},{"@type":"BreadcrumbList","@id":"https://www.merck.com/news/lynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://www.merck.com/news-archive/"},{"@type":"ListItem","position":2,"name":"LYNK-003 Trial Evaluating LYNPARZA® (olaparib) With or Without Bevacizumab in Patients With Unresectable or Metastatic Colorectal Cancer to Stop for Futility"}]}]}</script>
	<!-- / Yoast SEO plugin. -->


<link rel='dns-prefetch' href='http://s.w.org/' />
<link rel='dns-prefetch' href='http://v0.wordpress.com/' />
<link rel='stylesheet' id='single-news-styles-css'  href='../../wp-content/themes/mhh-merck-mco-theme/css/single-news_item.min873c.css?ver=20200302' media='all' />
<link rel='stylesheet' id='wp-block-library-css'  href='../../wp-includes/css/dist/block-library/style.min9bd2.css?ver=5.9.4' media='all' />
<style id='wp-block-library-inline-css'>
.has-text-align-justify{text-align:justify;}
</style>
<link rel='stylesheet' id='mediaelement-css'  href='../../wp-includes/js/mediaelement/mediaelementplayer-legacy.min08e1.css?ver=4.2.16' media='all' />
<link rel='stylesheet' id='wp-mediaelement-css'  href='../../wp-includes/js/mediaelement/wp-mediaelement.min9bd2.css?ver=5.9.4' media='all' />
<link rel='stylesheet' id='elasticpress-related-posts-block-css'  href='../../wp-content/mu-plugins/search/elasticpress/dist/css/related-posts-block-styles.min3ab2.css?ver=3.6.5' media='all' />
<style id='global-styles-inline-css'>
body{--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel='stylesheet' id='all-css-12' href='../../wp-content/plugins/seriously-simple-podcasting/assets/css/recent-episodes4fe0.css?m=1664556542g' type='text/css' media='all' />
<link rel='stylesheet' id='qm-objectcache-style-css'  href='../../wp-content/mu-plugins/qm-plugins/qm-object-cache/css/styleb3e8.css?ver=0.1' media='all' />
<link rel='stylesheet' id='Mco-styles-css'  href='../../wp-content/themes/mhh-merck-mco-theme/css/style.min367c.css?ver=20190301' media='all' />
<link rel="https://api.w.org/" href="../../wp-json/index.html" /><link rel="alternate" type="application/json" href="../../wp-json/wp/v2/news_item/3600690.json" /><link rel='shortlink' href='../../indexc0b6.html?p=3600690' />
<link rel="alternate" type="application/json+oembed" href="../../wp-json/oembed/1.0/embed1047.json?url=https%3A%2F%2Fwww.merck.com%2Fnews%2Flynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility%2F" />
<link rel="alternate" type="text/xml+oembed" href="../../wp-json/oembed/1.0/embed7040?url=https%3A%2F%2Fwww.merck.com%2Fnews%2Flynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility%2F&amp;format=xml" />

<link rel="alternate" type="application/rss+xml" title="Podcast RSS feed" href="../../feed/podcast" />

<script type="text/javascript">
var dataLayer = dataLayer || [];
dataLayer.push({"user":{"role":"visitor","isLoggedIn":false}});
dataLayer.push({"site":[]});
dataLayer.push({"page":{"page_wpid":"3600690","page_language":"en_us","page_lineofbusiness":"human health","page_accessibility":"publish","page_title":"lynk-003 trial evaluating lynparza\u00ae (olaparib) with or without bevacizumab in patients with unresectable or metastatic colorectal cancer to stop for futility"}});
</script>
<script type="text/javascript">
(
        function( w, d, s, l, i ) {
            w[l] = w[l] || [];
            w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} );
					var f = d.getElementsByTagName( s )[0],
						j = d.createElement( s ), dl = l !== 'dataLayer' ? '&l=' + l : '';
					j.async = true;
					j.src = '../../../www.googletagmanager.com/gtm5445.html?id=' + i + dl;
					f.parentNode.insertBefore( j, f );
				}
        )( window, document, 'script', 'dataLayer', 'GTM-M74WZDM' );
</script>
<meta name="page_wpid" content="3600690" /><meta name="page_language" content="en_US" /><meta name="page_lineofbusiness" content="Human Health" /><meta name="page_accessibility" content="publish" /><meta name="page_title" content="lynk-003 trial evaluating lynparza® (olaparib) with or without bevacizumab in patients with unresectable or metastatic colorectal cancer to stop for futility" />        <link rel="apple-touch-icon" sizes="180x180" href="../../wp-content/themes/mhh-merck-mco-theme/images/apple-touch-icon.png">
    <link rel="icon" type="image/png" sizes="32x32" href="../../wp-content/themes/mhh-merck-mco-theme/images/favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../../wp-content/themes/mhh-merck-mco-theme/images/favicon-16x16.png">

    <link rel="manifest" href="../../wp-content/themes/mhh-merck-mco-theme/images/site.webmanifest">
    <link rel="mask-icon" href="../../wp-content/themes/mhh-merck-mco-theme/images/safari-pinned-tab.svg" color="#ffffff">
    <link rel="shortcut icon" href="../../wp-content/themes/mhh-merck-mco-theme/images/favicon.ico">
    <meta name="msapplication-TileColor" content="#ffffff">
    <meta name="msapplication-config" content="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/browserconfig.xml">
    <meta name="theme-color" content="#ffffff">
    
<style>
    :root {
        --colorTextPrimary: #000000;
        --colorPrimary: #00857C;
        --colorPrimaryLight: #6ECEB2;
        --colorPrimaryDark: #005C55;
        --colorPrimaryDarkBlue: #0C2340;
        --colorSecondaryLime: #BFED33;
        --colorSecondaryLemon: #FFF063;
        --colorSecondaryPastelBlue: #69B8F7;
        --colorSecondaryVistaBlue: #688CE8;
        --colorSecondaryRichBlue: #5450E4;
        --colorBlack: #000000;
        --colorWhite: #FFFFFF;
        --colorOffWhite: #F7F7F7;
        --colorGray: #757575;
        --colorWarning: #FE0000;
        --colorSuccess: #029A01;
        --colorInfo: #1058A4;
        --colorGrayHRTwenty: #75757533;
        --colorGrayHRTen: #7575751a;
    }
</style> </head>

<body class="news_item-template-default single single-news_item postid-3600690 no-sidebar">
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M74WZDM&amp;user%5Brole%5D=visitor&amp;user%5BisLoggedIn%5D=0&amp;page%5Bpage_wpid%5D=3600690&amp;page%5Bpage_language%5D=en_us&amp;page%5Bpage_lineofbusiness%5D=human%20health&amp;page%5Bpage_accessibility%5D=publish&amp;page%5Bpage_title%5D=lynk-003%20trial%20evaluating%20lynparza%c2%ae%20(olaparib)%20with%20or%20without%20bevacizumab%20in%20patients%20with%20unresectable%20or%20metastatic%20colorectal%20cancer%20to%20stop%20for%20futility" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-dark-grayscale"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 0.49803921568627" /><feFuncG type="table" tableValues="0 0.49803921568627" /><feFuncB type="table" tableValues="0 0.49803921568627" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-grayscale"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 1" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0 1" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-purple-yellow"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.54901960784314 0.98823529411765" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0.71764705882353 0.25490196078431" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-blue-red"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 1" /><feFuncG type="table" tableValues="0 0.27843137254902" /><feFuncB type="table" tableValues="0.5921568627451 0.27843137254902" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-midnight"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 0" /><feFuncG type="table" tableValues="0 0.64705882352941" /><feFuncB type="table" tableValues="0 1" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-magenta-yellow"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.78039215686275 1" /><feFuncG type="table" tableValues="0 0.94901960784314" /><feFuncB type="table" tableValues="0.35294117647059 0.47058823529412" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-purple-green"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.65098039215686 0.40392156862745" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0.44705882352941 0.4" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-blue-orange"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.098039215686275 1" /><feFuncG type="table" tableValues="0 0.66274509803922" /><feFuncB type="table" tableValues="0.84705882352941 0.41960784313725" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><div id="page" class="site">
    <a class="skip-link screen-reader-text" href="#content">Skip to content</a>

    

    <header id="masthead" class="site-header">
                <nav id="site-navigation" class="main-navigation">
            <div class="wrapper header-wrapper">
                <div class="site-branding">
            <p class="site-title">
                <a href="../../index.html" rel="home" title="Merck.com">
            <img class="site-logo" src="../../wp-content/themes/mhh-merck-mco-theme/images/logo.jpeg" alt="Site logo" />
            </a>
            </p>
    </div><!-- .site-branding -->                <div id="mastheadMenu">
    <button id="siteSearchToggle" class="btn" aria-controls="primary-search" aria-expanded="false">
        <span class="menu-toggle-text-open">
            <img src="../../wp-content/themes/mhh-merck-mco-theme/images/search-white.svg" alt="menu icon" />
            <span>Search everything</span>
        </span>
        <span class="menu-toggle-text-close">
            <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg" alt="close icon" />Close        </span>
    </button>
    <button id="siteNavigationToggle" class="btn menu-toggle" aria-controls="primary-menu" aria-expanded="false">
        <span class="menu-toggle-text-open">
            <img src="../../wp-content/themes/mhh-merck-mco-theme/images/burger-white.svg" alt="menu icon" />Menu        </span>
        <span class="menu-toggle-text-close">
            <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg" alt="close icon" />Close        </span>
    </button>
</div>            </div><!-- .header-wrapper -->
        </nav><!-- #site-navigation -->
        <nav id="site-menu" class="main-menu">
	<div class="wrapper">
		<a class="menucrumb" href="#">Main menu</a>
		<div class="menu-main-menu-container"><ul id="menuMain" class="menu-main level-0 menu-open"><li id="menu-item-666469" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666469"><a href="../../company-overview/index.html">Company</a>
<ul class="level-1">
	<li id="menu-item-666471" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666471"><a href="../../company-overview/index.html">Company overview</a></li>
	<li id="menu-item-667007" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-667007"><a href="../../stories/index.html">Stories</a></li>
	<li id="menu-item-2773656" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2773656"><a href="../../company-overview/history/index.html">History</a></li>
	<li id="menu-item-666473" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666473"><a href="../../company-overview/esg/index.html">Environmental, Social &#038; Governance (ESG)</a>
	<ul class="level-2">
		<li id="menu-item-2388650" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2388650"><a href="../../company-overview/esg/index.html">ESG overview</a></li>
		<li id="menu-item-2388653" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2388653"><a href="../../company-overview/esg/philanthropy/index.html">Philanthropy</a></li>
		<li id="menu-item-2796573" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2796573"><a href="../../company-overview/esg/merck-medical-outreach-program/index.html">Merck Medical Outreach Program</a></li>
		<li id="menu-item-2798027" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2798027"><a href="../../company-overview/esg/impact-investing/index.html">Impact investing</a></li>
		<li id="menu-item-2804132" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2804132"><a href="../../company-overview/esg/transparency-disclosures/index.html">Transparency disclosures</a></li>
		<li id="menu-item-2808199" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2808199"><a href="../../company-overview/esg/esg-resources/index.html">ESG resources</a></li>
	</ul>
</li>
	<li id="menu-item-666474" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666474"><a href="../../company-overview/leadership/index.html">Leadership</a>
	<ul class="level-2">
		<li id="menu-item-666483" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666483"><a href="../../company-overview/leadership/index.html">Leadership overview</a></li>
		<li id="menu-item-666484" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666484"><a href="../../company-overview/leadership/board-of-directors/index.html">Board of directors</a></li>
		<li id="menu-item-666485" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666485"><a href="../../company-overview/leadership/executive-team/index.html">Executive team</a></li>
	</ul>
</li>
	<li id="menu-item-666475" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666475"><a href="../../company-overview/culture-and-values/index.html">Culture &amp; values</a>
	<ul class="level-2">
		<li id="menu-item-666488" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666488"><a href="../../company-overview/culture-and-values/index.html">Culture &#038; values overview</a></li>
		<li id="menu-item-666489" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666489"><a href="../../company-overview/culture-and-values/code-of-conduct/index.html">Code of conduct &amp; compliance</a></li>
	</ul>
</li>
	<li id="menu-item-666476" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666476"><a href="../../company-overview/diversity-and-inclusion/index.html">Diversity &amp; inclusion</a></li>
	<li id="menu-item-666477" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666477"><a href="../../company-overview/policies-and-positions/index.html">Policies &amp; positions</a></li>
	<li id="menu-item-666478" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666478"><a href="../../company-overview/business-development-licensing/index.html">Business development &amp; licensing</a></li>
	<li id="menu-item-666479" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666479"><a href="../../company-overview/suppliers/index.html">Suppliers</a>
	<ul class="level-2">
		<li id="menu-item-667793" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-667793"><a href="../../company-overview/suppliers/index.html">Suppliers overview</a></li>
		<li id="menu-item-667792" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-667792"><a target="_blank" rel="noopener" href="https://msd.quantumsds.com/">Supplier registration</a></li>
		<li id="menu-item-3601080" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3601080"><a href="https://suppliers.msd.com/">Supplier help for Ariba</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-14540" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-14540"><a href="../../research/index.html">Research</a>
<ul class="level-1">
	<li id="menu-item-666505" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666505"><a href="../../research/index.html">Research overview</a></li>
	<li id="menu-item-2388262" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-2388262"><a href="../../research/covid-19/index.html">Our COVID-19 efforts</a></li>
	<li id="menu-item-666527" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-666527"><a target="_blank" rel="noopener" href="#">Areas of focus</a>
	<ul class="level-2">
		<li id="menu-item-666509" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666509"><a href="../../research/oncology/index.html">Oncology</a></li>
		<li id="menu-item-666507" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666507"><a href="../../research/vaccines/index.html">Vaccines</a></li>
		<li id="menu-item-666508" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666508"><a href="../../research/infectious-diseases/index.html">Infectious diseases</a></li>
		<li id="menu-item-666510" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666510"><a href="../../research/cardio-metabolic-disorders/index.html">Cardio-metabolic disorders</a></li>
	</ul>
</li>
	<li id="menu-item-666511" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666511"><a href="../../research/product-pipeline/index.html">Pipeline</a></li>
	<li id="menu-item-666512" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666512"><a href="../../research/discovery-development/index.html">Discovery &amp; development</a></li>
	<li id="menu-item-3600289" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3600289"><a href="../../research/rd-locations/index.html">R&#038;D locations</a></li>
	<li id="menu-item-666513" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666513"><a href="../../research/clinical-trials/index.html">Clinical trials</a>
	<ul class="level-2">
		<li id="menu-item-666673" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666673"><a href="../../research/clinical-trials/index.html">Clinical trials overview</a></li>
		<li id="menu-item-666672" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-666672"><a target="_blank" rel="noopener" href="https://www.merckclinicaltrials.com/">Find a trial</a></li>
		<li id="menu-item-2805336" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2805336"><a href="../../research/diversity-in-clinical-trials/index.html">Diversity in clinical trials</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-3600254" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3600254"><a href="../../products/index.html">Products</a>
<ul class="level-1">
	<li id="menu-item-666506" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666506"><a href="../../products/index.html">Products list</a></li>
	<li id="menu-item-666515" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666515"><a href="../../products/patent/index.html">Product patents</a></li>
	<li id="menu-item-14541" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-14541"><a href="../../products/distributors/index.html">Merck authorized distributors</a></li>
</ul>
</li>
<li id="menu-item-628574" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-628574"><a href="../../patients/index.html">Patients</a>
<ul class="level-1">
	<li id="menu-item-2784133" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2784133"><a href="../../patients/index.html">Patients overview</a></li>
	<li id="menu-item-2181846" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2181846"><a href="../../patients/patient-financial-assistance/index.html">Patient support programs</a></li>
	<li id="menu-item-628576" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-628576"><a href="../../patients/patient-resources/index.html">Patient resources</a></li>
	<li id="menu-item-628575" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-628575"><a href="../../patients/patient-and-treatment-education/index.html">Patient &amp; treatment education</a></li>
</ul>
</li>
<li id="menu-item-666493" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-666493"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en">Careers</a>
<ul class="level-1">
	<li id="menu-item-696146" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696146"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/home">Careers</a></li>
	<li id="menu-item-696145" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696145"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/search-results">Search jobs</a></li>
	<li id="menu-item-696144" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-696144"><a href="#">Our divisions</a>
	<ul class="level-2">
		<li id="menu-item-696175" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696175"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/research-laboratories">Research &#038; development</a></li>
		<li id="menu-item-696174" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696174"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/manufacturing">Manufacturing &#038; supply</a></li>
		<li id="menu-item-696172" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696172"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/human-health">Human Health</a></li>
		<li id="menu-item-696171" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696171"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/animal-health">Animal Health</a></li>
		<li id="menu-item-696164" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696164"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/global-support-functions">Global support functions</a></li>
	</ul>
</li>
	<li id="menu-item-696141" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696141"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/veteran-opportunities">Veterans</a></li>
	<li id="menu-item-696140" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696140"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/student-opportunities">Student opportunities</a></li>
	<li id="menu-item-696139" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696139"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/compensation-and-benefits">Compensation &#038; benefits</a></li>
	<li id="menu-item-696138" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696138"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/hiring-process">How we hire</a></li>
	<li id="menu-item-696137" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696137"><a target="_blank" rel="noopener" href="https://jobs.msd.com/gb/en/home">MSD Careers</a></li>
	<li id="menu-item-696136" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696136"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/events">Events</a></li>
	<li id="menu-item-696134" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696134"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/jointalentcommunity?applyType=JTC">Talent community</a></li>
</ul>
</li>
<li id="menu-item-137022" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-137022"><a href="../../investor-relations/index.html">Investors</a>
<ul class="level-1">
	<li id="menu-item-223087" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-223087"><a href="../../investor-relations/index.html">Investors overview</a></li>
	<li id="menu-item-220674" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-220674"><a href="../../investor-relations/events-and-presentations/index.html">Events &amp; presentations</a></li>
	<li id="menu-item-220673" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-220673"><a href="../../investor-relations/financial-information/index.html">Financial information</a>
	<ul class="level-2">
		<li id="menu-item-666494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666494"><a href="../../investor-relations/financial-information/index.html">Financial information overview</a></li>
		<li id="menu-item-666495" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666495"><a href="../../investor-relations/financial-information/sec-filings/index.html">SEC filings</a></li>
	</ul>
</li>
	<li id="menu-item-220672" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-220672"><a href="../../investor-relations/stock-info/index.html">Stock information</a></li>
	<li id="menu-item-220671" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-220671"><a href="../../investor-relations/investor-resources/index.html">Investor resources</a>
	<ul class="level-2">
		<li id="menu-item-666496" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666496"><a href="../../investor-relations/investor-resources/index.html">Investor resources overview</a></li>
		<li id="menu-item-2793045" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2793045"><a href="../../investor-relations/organon-resources/index.html">Organon resources</a></li>
		<li id="menu-item-666497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666497"><a href="../../investor-relations/investor-resources/information-request/index.html">Request for information</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-650872" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-650872"><a href="../../media/index.html">Media</a>
<ul class="level-1">
	<li id="menu-item-650874" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650874"><a href="../../media/index.html">Media overview</a></li>
	<li id="menu-item-650878" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650878"><a href="../../media/news/index.html">News releases</a></li>
	<li id="menu-item-650884" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650884"><a href="../../media/company-statements/index.html">Company statements</a></li>
	<li id="menu-item-3544562" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3544562"><a href="../../media/media-library/index.html">Media library &amp; contacts</a>
	<ul class="level-2">
		<li id="menu-item-3544537" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3544537"><a href="../../media/media-library/index.html">Media contact &#038; library overview</a></li>
		<li id="menu-item-650879" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650879"><a href="../../media/media-library/company-fact-sheet/index.html">Company fact sheet</a></li>
	</ul>
</li>
</ul>
</li>
</ul></div>		<div class="side-section">
															<div class="image">
						<picture>
							<source media="(max-width: 1279px)"
								data-srcset="../../wp-content/uploads/sites/5/2021/11/covid-19-response-heroceb3.jpg?resize=370,418">
							<source media="(min-width: 1280px)"
								data-srcset="../../wp-content/uploads/sites/5/2021/11/covid-19-response-herof9f6.jpg?resize=486,432">
							<img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/uploads/sites/5/2021/11/covid-19-response-hero.jpg?resize=486,432" alt="two scientists wearing masks">
						</picture>
					</div>
													<div class="tagline"></div>
													<h4>Our COVID-19 efforts</h4>
													<a class="btn" href="../../research/covid-19/index.html" title="Learn more" target="">Learn more</a>
									</div>
		<div class="bottom-section">
			<a class="btn" href="../../contact-us/index.html">Contact us</a>
			<p>
				<a href="https://www.msd.com/contact-us/worldwide-locations/" target="_blank" rel="noopener">Worldwide</a>
				<small>Countries outside of the United States and Canada.</small>
			</p>
		</div>
	</div>
</nav><!-- #site-menu -->

        <form id="site-search" role="search" method="get" class="search-form" action="https://www.merck.com/" autocomplete="off">
    <h1>What can we help you find?</h1>
    <div id="site-search-box" class="input-box autocomplete">
        <span class="screen-reader-text">Search for:</span>
        <input type="text" class="search-field autocomplete-input" placeholder="Search here …" value="" name="s" aria-label="Search site">
        <button type="submit" class="submit search-submit"></button>
    </div>
    <div id="search_suggestion_result"></div> 
    </form>


<script>
    theme_directory = "../../wp-content/themes/mhh-merck-mco-theme/index.html";  
</script>
    </header><!-- #masthead -->
    <div id="content" class="site-content">


	<div id="primary" class="content-area">
                    <div class="breadcrumbs wrapper text-descriptive">
                <span>
                    <span>
                        <a href="../../media/index.html">
                            Media
                        </a> &gt; 
                        <span>
                            <a href="../../media/company-statements/index.html">
                                Company statements
                            </a> &gt; 
                            <span class="breadcrumb_last" aria-current="page">
                                Company statement
                            </span>
                        </span>
                    </span>
                </span>
            </div>
        		<main id="main" class="site-main single-news_item">
            <article id="post-3600690" class="post-3600690 news_item type-news_item status-publish hentry tag-company-statement">

                <div class="entry-content">
                    <div class="news-itm-header-container wrapper">
                        <div>
                            <h2 class="entry-title">
                                LYNK-003 Trial Evaluating LYNPARZA® (olaparib) With or Without Bevacizumab in Patients With Unresectable or Metastatic Colorectal Cancer to Stop for Futility                            </h2>
                        </div>
                    </div>

                    <div class="wrapper">
                        <div class="entry-header-links-div">
                                                            <a href="#" onclick="window.print()"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 16 16">
    <path fill="#00857C" d="M14 5.25a.75.75 0 0 1 .743.648L14.75 6v6a.75.75 0 0 1-.648.743L14 12.75h-2.182l-.068-.005V14a.75.75 0 0 1-.648.743L11 14.75H5a.75.75 0 0 1-.75-.75v-1.255l-.068.005H2a.75.75 0 0 1-.743-.648L1.25 12V6a.75.75 0 0 1 .648-.743L2 5.25h12zm-3.75 5.5h-4.5v2.5h4.5v-2.5zm3-4H2.75v4.5h1.432l.068.004V10a.75.75 0 0 1 .648-.743L5 9.25h6a.75.75 0 0 1 .75.75v1.254l.068-.004h1.432v-4.5zM12 1.25a.75.75 0 0 1 .743.648L12.75 2v3h-1.5V2.75h-6.5V5h-1.5V2a.75.75 0 0 1 .648-.743L4 1.25h8z" />
</svg>
 Print</a>
                                                    </div>
                        
                        <div class="news-item-text-container">
                            <p class="date-text">
                                July 18, 2022 4:00 pm ET                            </p>
                            
<p>RAHWAY, N.J., July 18, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, will stop for futility the Phase 3 LYNK-003 trial investigating LYNPARZA with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction. This action follows the recommendation of an independent Data Monitoring Committee (DMC), after the DMC reviewed the data from a planned interim analysis. LYNPARZA is a PARP inhibitor that is being co-developed and co-commercialized with AstraZeneca.</p>



<p>At the pre-specified interim analysis for progression-free survival, the efficacy of LYNPARZA as a monotherapy and in combination with bevacizumab relative to control met the criteria for futility by the DMC and accordingly, both experimental arms will be discontinued. No new safety signals were observed with LYNPARZA in this trial, and the safety profiles of both LYNPARZA monotherapy and LYNPARZA combined with bevacizumab in this trial were generally consistent with that observed in previously reported studies. Merck will inform study investigators of the recommendation from the DMC and will advise patients in the trial to speak to their physician regarding treatment options. Data from this study will be shared in a future scientific forum.</p>



<p>LYNK-003 is one of several trials initiated by Merck as part of the extensive LYNPARZA clinical development program. In addition to colorectal cancer, LYNPARZA is also being studied by Merck, in collaboration with AstraZeneca, as both monotherapy and in new combinations across a range of DNA damage response deficient tumor types, including metastatic prostate cancer, ovarian cancer, breast cancer and pancreatic cancer.</p>



<p><strong>About LYNK-003</strong></p>



<p>LYNK-003 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, <a href="https://clinicaltrials.gov/ct2/show/NCT04456699" target="_blank" rel="noreferrer noopener">NCT04456699</a>) evaluating LYNPARZA in combination with bevacizumab and as monotherapy compared to bevacizumab in combination with fluoropyrimidine-based chemotherapy in 309 patients with unresectable or metastatic colorectal cancer who had not progressed following first-line induction. The primary endpoint is PFS, and secondary endpoints include OS, objective response rate, duration of response and safety.</p>



<p><strong>About Colorectal Cancer</strong></p>



<p>Colorectal cancer starts in the colon or the rectum, and these cancers are referred to as colon cancer or rectal cancer depending on where the cancer starts. Colorectal cancer often begins with growths on the inner lining of the colon or rectum called polyps, which can change into cancer over time. Worldwide, colorectal cancer is the third most common cancer and is the second leading cause of cancer death, with 1,932,000 new cases diagnosed and 935,000 deaths from the disease in 2020. In the United States, it is estimated there will be more than 106,000 new cases of colon cancer and nearly 45,000 new cases of rectal cancer diagnosed, and nearly 53,000 deaths from colorectal cancer in 2022.</p>



<p><strong>About LYNPARZA<sup>®</sup> (olaparib)</strong></p>



<p>LYNPARZA is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as <em>BRCA</em> mutations, to preferentially kill cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death. LYNPARZA is being tested in a range of tumor types with defects and dependencies in the DDR.</p>



<p>LYNPARZA, which is being jointly developed and commercialized by AstraZeneca and Merck, has a broad and advanced clinical trial development program, and AstraZeneca and Merck are working together to understand how it may affect multiple PARP-dependent tumors as a monotherapy and in combination across multiple cancer types.</p>



<p><strong>IMPORTANT SAFETY INFORMATION</strong></p>



<p><strong>CONTRAINDICATIONS</strong></p>



<p>There are no contraindications for LYNPARZA.</p>



<p><strong>WARNINGS AND PRECAUTIONS</strong></p>



<p><strong>Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): </strong>Occurred in approximately 1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome. The median duration of therapy in patients who developed MDS/AML was 2 years (range: &lt;6 months to &gt;10 years). All of these patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy.</p>



<p>Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly until recovery.</p>



<p>If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA if MDS/AML is confirmed.</p>



<p><strong>Pneumonitis: </strong>Occurred in 0.8% of patients exposed to LYNPARZA monotherapy, and some cases were fatal. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is confirmed and treat patient appropriately.</p>



<p><strong>Embryo-Fetal Toxicity: </strong>Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is recommended for females of reproductive potential prior to initiating treatment.</p>



<p><em>Females</em></p>



<p>Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 6 months following the last dose.</p>



<p><em>Males</em></p>



<p>Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of LYNPARZA and to not donate sperm during this time.</p>



<p><strong>Venous Thromboembolic Events:</strong> Including pulmonary embolism, occurred in 7% of patients with metastatic castration-resistant prostate cancer who received LYNPARZA plus androgen deprivation therapy (ADT) compared to 3.1% of patients receiving enzalutamide or abiraterone plus ADT in the PROfound study. Patients receiving LYNPARZA and ADT had a 6% incidence of pulmonary embolism compared to 0.8% of patients treated with ADT plus either enzalutamide or abiraterone. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism, and treat as medically appropriate, which may include long-term anticoagulation as clinically indicated.</p>



<p><strong>ADVERSE REACTIONS—First-Line Maintenance <em>BRCA</em>m Advanced Ovarian Cancer</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA in the <strong>first-line maintenance setting</strong> for <strong>SOLO-1 </strong>were: nausea (77%), fatigue (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%), upper respiratory tract infection/influenza/nasopharyngitis/bronchitis (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), urinary tract infection (13%), thrombocytopenia (11%), and stomatitis (11%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the <strong>first-line maintenance setting for SOLO-1</strong> were: decrease in hemoglobin (87%), increase in mean corpuscular volume (87%), decrease in leukocytes (70%), decrease in lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease in platelets (35%), and increase in serum creatinine (34%).</p>



<p><strong>ADVERSE REACTIONS—First-Line Maintenance Advanced Ovarian Cancer in Combination with Bevacizumab</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥10% of patients treated with LYNPARZA/bevacizumab compared to a ≥5% frequency for placebo/bevacizumab in the <strong>first-line maintenance setting</strong> for <strong>PAOLA-1</strong> were: nausea (53%), fatigue (including asthenia) (53%), anemia (41%), lymphopenia (24%), vomiting (22%) and leukopenia (18%). In addition, the most common adverse reactions (≥10%) for patients receiving LYNPARZA/bevacizumab irrespective of the frequency compared with the placebo/bevacizumab arm were: diarrhea (18%), neutropenia (18%), urinary tract infection (15%) and headache (14%).</p>



<p>In addition, venous thromboembolic events occurred more commonly in patients receiving LYNPARZA/bevacizumab (5%) than in those receiving placebo/bevacizumab (1.9%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients for LYNPARZA in combination with bevacizumab in the <strong>first-line maintenance setting</strong> for <strong>PAOLA-1</strong> were: decrease in hemoglobin (79%), decrease in lymphocytes (63%), increase in serum creatinine (61%), decrease in leukocytes (59%), decrease in absolute neutrophil count (35%) and decrease in platelets (35%).</p>



<p><strong>ADVERSE REACTIONS—Maintenance Recurrent Ovarian Cancer</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥20% of patients who received LYNPARZA in the <strong>maintenance setting </strong>for <strong>SOLO-2</strong> were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%), nasopharyngitis/upper respiratory tract infection (URI)/influenza (36%), diarrhea (33%), arthralgia/myalgia (30%), dysgeusia (27%), headache (26%), decreased appetite (22%), and stomatitis (20%).</p>



<p><strong>Study 19: </strong>nausea (71%), fatigue (including asthenia) (63%), vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%), constipation (22%), headache (21%), decreased appetite (21%) and dyspepsia (20%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the <strong>maintenance setting (SOLO-2/Study 19</strong>) were: increase in mean corpuscular volume (89%/82%), decrease in hemoglobin (83%/82%), decrease in leukocytes (69%/58%), decrease in lymphocytes (67%/52%), decrease in absolute neutrophil count (51%/47%), increase in serum creatinine (44%/45%), and decrease in platelets (42%/36%).</p>



<p><strong>ADVERSE REACTIONS—Advanced g<em>BRCA</em>m Ovarian Cancer After 3 or More Lines of Chemotherapy</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥20% of patients who received</p>



<p>LYNPARZA for <strong>advanced g<em>BRCA</em>m ovarian cancer after 3 or more lines of chemotherapy </strong>(pooled from 6 studies) were: fatigue/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%), diarrhea (31%), nasopharyngitis/upper respiratory tract infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and arthralgia/musculoskeletal pain (21%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA for <strong>advanced g<em>BRCA</em>m ovarian cancer </strong>(pooled from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular volume elevation (57%), decrease in lymphocytes (56%), increase in serum creatinine (30%), decrease in platelets (30%), and decrease in absolute neutrophil count (25%).</p>



<p><strong>ADVERSE REACTIONS—Adjuvant Treatment of g<em>BRCA</em>m, HER2-Negative, High-Risk Early Breast Cancer</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA in the <strong>adjuvant setting</strong> for <strong>OlympiA</strong> were: nausea (57%), fatigue (including asthenia) (42%), anemia (24%), vomiting (23%), headache (20%), diarrhea (18%), leukopenia (17%), neutropenia (16%), decreased appetite (13%), dysgeusia (12%), dizziness (11%), and stomatitis (10%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the <strong>adjuvant setting </strong>for <strong>OlympiA</strong> were: decrease in lymphocytes (77%), increase in mean corpuscular volume (67%), decrease in hemoglobin (65%), decrease in leukocytes (64%), and decrease in absolute neutrophil count (39%).</p>



<p><strong>ADVERSE REACTIONS—g<em>BRCA</em>m, HER2-Negative Metastatic Breast Cancer</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥20% of patients who received LYNPARZA in the <strong>metastatic setting</strong> for <strong>OlympiAD</strong> were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in &gt;25% of patients who received LYNPARZA in the <strong>metastatic setting</strong> for <strong>OlympiAD </strong>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%), decrease in leukocytes (71%), increase in mean corpuscular volume (71%), decrease in absolute neutrophil count (46%), and decrease in platelets (33%).</p>



<p><strong>ADVERSE REACTIONS—First-Line Maintenance g<em>BRCA</em>m Metastatic Pancreatic Adenocarcinoma</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA in the&nbsp;<strong>first-line maintenance setting</strong>&nbsp;for&nbsp;<strong>POLO&nbsp;</strong>were: fatigue (60%), nausea (45%), abdominal pain (34%), diarrhea (29%), anemia (27%), decreased appetite (25%), constipation (23%), vomiting (20%), back pain (19%), arthralgia (15%), rash (15%), thrombocytopenia (14%), dyspnea (13%), neutropenia (12%), nasopharyngitis (12%), dysgeusia (11%), and stomatitis (10%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the <strong>first-line maintenance setting</strong> for <strong>POLO</strong> were: increase in serum creatinine (99%), decrease in hemoglobin (86%), increase in mean corpuscular volume (71%), decrease in lymphocytes (61%), decrease in platelets (56%), decrease in leukocytes (50%), and decrease in absolute neutrophil count (25%).</p>



<p><strong>ADVERSE REACTIONS—HRR Gene-mutated Metastatic Castration Resistant Prostate Cancer</strong></p>



<p>Most common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA for <strong>PROfound</strong> were: anemia (46%), fatigue (including asthenia) (41%), nausea (41%), decreased appetite (30%), diarrhea (21%), vomiting (18%), thrombocytopenia (12%), cough (11%), and dyspnea (10%).</p>



<p>Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA for <strong>PROfound</strong> were: decrease in hemoglobin (98%), decrease in lymphocytes (62%), decrease in leukocytes (53%), and decrease in absolute neutrophil count (34%).</p>



<p><strong>DRUG INTERACTIONS</strong></p>



<p><strong>Anticancer Agents: </strong>Clinical studies of LYNPARZA with other myelosuppressive anticancer agents, including DNA-damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.</p>



<p><strong>CYP3A Inhibitors: </strong>Avoid coadministration of strong or moderate CYP3A inhibitors when using LYNPARZA. If a strong or moderate CYP3A inhibitor must be coadministered, reduce the dose of LYNPARZA. Advise patients to avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during LYNPARZA treatment.</p>



<p><strong>CYP3A Inducers: </strong>Avoid coadministration of strong or moderate CYP3A inducers when using LYNPARZA.</p>



<p><strong>USE IN SPECIFIC POPULATIONS</strong></p>



<p><strong>Lactation: </strong>No data are available regarding the presence of olaparib in human milk, its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infant, advise a lactating woman not to breastfeed during treatment with LYNPARZA and for 1 month after receiving the final dose.</p>



<p><strong>Pediatric Use: </strong>The safety and efficacy of LYNPARZA have not been established in pediatric patients.</p>



<p><strong>Hepatic Impairment: </strong>No adjustment to the starting dose is required in patients with mild or moderate hepatic impairment (Child-Pugh classification A and B). There are no data in patients with severe hepatic impairment (Child-Pugh classification C).</p>



<p><strong>Renal Impairment: </strong>No dosage modification is recommended in patients with mild renal impairment (CLcr 51-80 mL/min estimated by Cockcroft-Gault). In patients with moderate renal impairment (CLcr 31-50 mL/min), reduce the dose of LYNPARZA to 200 mg twice daily. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min).</p>



<p><strong>INDICATIONS for LYNPARZA in the United States</strong></p>



<p>LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for:</p>



<p><strong>First-Line Maintenance <em>BRCA</em>m Advanced Ovarian Cancer</strong></p>



<p>For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic <em>BRCA</em>-mutated (g<em>BRCA</em>m or s<em>BRCA</em>m) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.</p>



<p><strong>First-Line Maintenance HRD-Positive Advanced Ovarian Cancer in Combination with Bevacizumab</strong></p>



<p>In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:</p>



<ul><li>a deleterious or suspected deleterious <em>BRCA</em> mutation and/or</li><li>genomic instability</li></ul>



<p>Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.</p>



<p><strong>Maintenance Recurrent Ovarian Cancer</strong></p>



<p>For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.</p>



<p><strong>Advanced g<em>BRCA</em>m Ovarian Cancer</strong></p>



<p>For the treatment of adult patients with deleterious or suspected deleterious germline <em>BRCA-</em>mutated (g<em>BRCA</em>m) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.</p>



<p><strong>Adjuvant Treatment of g<em>BRCA</em>m, HER2-Negative, High-Risk Early Breast Cancer</strong></p>



<p>For the adjuvant treatment of adult patients with deleterious or suspected deleterious g<em>BRCA</em>m, human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.</p>



<p><strong>g<em>BRCA</em>m HER2-Negative Metastatic Breast Cancer</strong></p>



<p>For the treatment of adult patients with deleterious or suspected deleterious g<em>BRCA</em>m<em>,</em> human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.</p>



<p><strong>First-Line Maintenance g<em>BRCA</em>m Metastatic Pancreatic Cancer</strong></p>



<p>For the maintenance treatment of adult patients with deleterious or suspected deleterious g<em>BRCA</em>m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.</p>



<p><strong>HRR Gene-mutated Metastatic Castration Resistant Prostate Cancer</strong></p>



<p>For the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.</p>



<p><strong>Please see complete </strong><a href="https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/00997c3f-5912-486f-a7db-930b4639cd51/00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf" target="_blank" rel="noreferrer noopener"><strong>Prescribing Information</strong></a><strong>, including </strong><a href="https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/00997c3f-5912-486f-a7db-930b4639cd51/00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf#page=17" target="_blank" rel="noreferrer noopener"><strong>Medication Guide</strong></a><strong>.</strong></p>



<p><strong>About </strong><strong>the AstraZeneca and Merck </strong><strong>strategic oncology collaboration</strong><strong> </strong><strong></strong></p>



<p>In July 2017, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced a global strategic oncology collaboration to co-develop and co-commercialize certain oncology products including LYNPARZA, the world’s first PARP inhibitor, for multiple cancer types. Working together, the companies will develop&nbsp;these products&nbsp;in combination with other potential new medicines and as monotherapies. Independently, the companies will develop these oncology products in combination with their respective PD-L1 and PD-1 medicines.</p>



<p><strong>Merck’s focus on cancer</strong></p>



<p>Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit&nbsp;<a href="https://www.merckclinicaltrials.com/">www.merck.com/clinicaltrials</a>.</p>



<p><strong>About Merck</strong><strong></strong></p>



<p>At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.&nbsp;For more information, visit&nbsp;<a href="../../index.html">www.merck.com</a>&nbsp;and connect with us on&nbsp;<a href="https://twitter.com/Merck" target="_blank" rel="noreferrer noopener">Twitter</a>,&nbsp;<a href="https://www.facebook.com/MerckInvents/" target="_blank" rel="noreferrer noopener">Facebook</a>,&nbsp;<a href="https://www.instagram.com/merck/" target="_blank" rel="noreferrer noopener">Instagram</a>,&nbsp;<a href="http://www.youtube.com/Merck" target="_blank" rel="noreferrer noopener">YouTube</a>&nbsp;and&nbsp;<a href="https://www.linkedin.com/company/merck" target="_blank" rel="noreferrer noopener">LinkedIn</a>.</p>



<p><strong>Forward-Looking Statement of Merck &amp; Co., Inc., Rahway, N.J., USA</strong></p>



<p>This statement of Merck &amp; Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.</p>



<p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.</p>



<p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (<a href="http://www.sec.gov/" target="_blank" rel="noreferrer noopener">www.sec.gov</a>).</p>



<p>###</p>



<p><strong>Media Contacts:</strong></p>



<p>Melissa Moody 215-407-3536</p>



<p>Chrissy Trank 640-650-0694</p>



<p id="block-00f8e72d-2fcd-4227-9271-eb16d6ac3a10"><strong>Investor Contacts:</strong></p>



<p id="block-42a895b2-6bef-469d-8f55-1a3f9ef3aaac">Peter Dannenbaum 908-740-1037</p>



<p>Damini Chokshi 908-740-1807</p>
                        </div>
                        
                    </div>      

                                    </div><!-- .entry-content -->
                <div class="opt-in-communication-wrapper wrapper no-secondary-image" id="opt-in-communication-block-block_5e949a66cfcc9" aria-hidden="true">

                    <div class="opt-in-communication-block img-wrapper" style="position: relative;">
                        <picture class="opt-in-primary-img">
                            <source media="(max-width: 767px)" srcset="../../wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-1a83.png?resize=321,196">
                            <source media="(min-width: 768px) and (max-width: 1279px)" srcset="../../wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-bf9a.png?resize=656,432">
                            <source media="(min-width: 1280px)" srcset="../../wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-7361.png?resize=516,596">
                            <img class="opt-in-primary-img lazyload" loading="lazy" src="../../wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-7361.png?resize=516,596" alt="opt-in primary image"/>
                        </picture>
                    </div>

                    <div class="opt-in-left">
                        <div class="opt-in-left-content">
                                <h2 class="opt-in-title">Sign up for email alerts</h2>
                            <p class="opt-in-caption"></p>
                        </div>
                        <div class="opt-in-communication-block-iframe-holder">
                            <iframe id="opt-in-communication-block-block_5e949a66cfcc9-iFrame" src="https://merck2016rd.q4web.com/Email-Signup-New-Release/" style="width: 100%; overflow: hidden; height: 491px;" scrolling="no" frameborder="0"></iframe>
                            <script>
                                try {
                                    function iFrameResizerDefer(method) { if (typeof iFrameResize === "function") { method(); } else { setTimeout(function() { iFrameResizerDefer(method) }, 50); } }
                                    document.getElementById('opt-in-communication-block-block_5e949a66cfcc9-iFrame').onload = function() { iFrameResize({log:false}); };
                                } catch(ex) {
                                    console.log(ex);
                                } 
                            </script>

                        </div>
                    </div>

                </div>
                <p class="wrapper"><a href="../../investor-relations/email-alerts/index.html" class="btn secondary">Unsubscribe from email alerts</a></p>
                <footer class="entry-footer">
                                    </footer><!-- .entry-footer -->
            </article><!-- #post-3600690 -->
		
        </main><!-- #main -->
	</div><!-- #primary -->
    
    <div class="related-content-container">
        <h4>Related links</h4>
        <div class="related-content-section">
            <div class="related-content-item">
                <a href="../../media/company-statements/index.html">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png" alt="related content image #1"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>Company Statements</strong></p>
                        <p class="realted-content-excerpt">Read our latest company statements.</p>
                    </div>
                </a>
            </div>

            <div class="related-content-item">
                <a href="../../media/media-library/index.html">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png" alt="related content image #2"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>Media library</strong></p>
                        <p class="realted-content-excerpt">Access videos, logos, photos, and infographics.</p>
                    </div>
                </a>
            </div>

            <div class="related-content-item">
                <a href="../../company-overview/index.html">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png" alt="related content image #3"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>About Merck</strong></p>
                        <p class="realted-content-excerpt">We are committed to providing leading innovations for today and the future that save and improve lives around the world.</p>
                    </div>
                </a>
            </div>
        </div>
    </div>

</div><!-- #content -->
<footer id="footerMain" class="footer">
    <div id="footerSocial">
        <div class="wrapper">
            <h3>Connect with us on social</h3>
            <div class="social-icons">
                                    <a href="https://twitter.com/Merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/twitter-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.facebook.com/MerckInvents" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/facebook-f-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.linkedin.com/company/merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/linkedin-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.instagram.com/merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/instagram-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.youtube.com/user/Merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/youtube-brands.svg" alt="social icon" />
                    </a>
                            </div>
        </div>
    </div>
    <div class="wrapper">
        <div id="footerPrograms">
                            <div class="column col-one">
                    <input type="checkbox" id="columnOne" class="checkbox-toggle">
                    <label for="columnOne" class="column-header">For patients and health care professionals</label>
                    <ul>
                        <li><a href="https://www.merckhelps.com/" target="_blank" rel="noopener">MerckHelps</a><br>
                            Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients</li>
                        <li><a href="https://www.merckaccessprogram.com/" target="_blank" rel="noopener">Merck Access Program</a><br>
                            Information about insurance coverage and financial assistance options for eligible patients</li>
                        <li><a href="https://www.merckclinicaltrials.com/" target="_blank" rel="noopener">Clinical trials</a><br>
                            Learn about our clinical trials and find available studies</li>
                        <li><a href="https://www.merckmanuals.com/" target="_blank" rel="noopener">Merck Manuals</a><br>
                            Medical information source covering thousands of topics in all fields of medicine</li>
                    </ul>
                </div>
            
                            <div class="column col-two">
                    <input type="checkbox" id="columnTwo" class="checkbox-toggle">
                    <label for="columnTwo" class="column-header">Environmental, Social &amp; Governance (ESG)</label>
                    <ul>
                                                    <li>
                                <a href="../../company-overview/esg/index.html" target="_blank" rel="noopener">Environmental, Social &amp; Governance (ESG) Report</a>
                                                                    <br />
                                    Reporting on our commitment to operating responsibly to benefit society                                                            </li>
                                                    <li>
                                <a href="https://www.merckformothers.com/" target="_blank" rel="noopener">Merck for Mothers</a>
                                                                    <br />
                                    An initiative to create a world where no woman has to die giving life                                                            </li>
                                            </ul>
                </div>
            
                            <div class="column col-three">
                    <input type="checkbox" id="columnThree" class="checkbox-toggle">
                    <label for="columnThree" class="column-header">About Merck</label>
                    <ul>
                        <li><a href="https://www.merck-animal-health.com/" target="_blank" rel="noopener">Merck Animal Health</a><br>
                            The global animal health business unit of Merck</li>
                        <li><a href="https://horizonblue.sapphiremrfhub.com/tocs/current/merck-co-inc" target="_blank" rel="noopener">Health Plan - Transparency in Coverage</a><br>
                            In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.</li>
                    </ul>
                </div>
                    </div>
        <div id="footerCopyrightLogos">
            <div id="footerCopyright">
                		<div class="menu-footer-menu-container"><ul id="menuFooter" class="footer-links"><li id="menu-item-674051" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-674051"><a href="../../forward-looking-statement/index.html">Forward-looking statement</a></li>
<li id="menu-item-137027" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137027"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/cookie-privacy-policy.html">Cookie policy</a></li>
<li id="menu-item-763862" class="ot-sdk-show-settings menu-item menu-item-type-custom menu-item-object-custom menu-item-763862"><a href="#">Cookie Preferences</a></li>
<li id="menu-item-137025" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137025"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/index.html">Privacy</a></li>
<li id="menu-item-137028" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137028"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/transparency-and-privacy.html">Transparency disclosure</a></li>
<li id="menu-item-669400" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-669400"><a href="../../terms-of-use/index.html">Terms of use</a></li>
<li id="menu-item-3374425" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3374425"><a href="https://www.msdaccessibility.com/">Accessibility</a></li>
<li id="menu-item-669401" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-669401"><a href="../../sitemap/index.html">Sitemap</a></li>
</ul></div>                <small>
                    Copyright © 2022  <a href="https://www.myknot.club/">MyKnot</a>; Co., India and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.                h-merck-mco-theme/images/logo.jpeg"         </small>
            </div>
            <div id="footerLogos">
                                <a href="https://www.essentialaccessibility.com/merck/?utm_source=merckhomepage&amp;utm_medium=iconlarge&amp;utm_term=eachannelpage&amp;utm_content=header&amp;utm_campaign=merck" target="_blank" rel="noopener">
                    <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/accessibility.png" alt="Accessibility icon" />
                </a>
                <!-- Truste badges -->
                <a href="http://privacy.truste.com/privacy-seal/validation?rid=140649f5-9394-46e8-bfe5-b4ea8a8c600e" target="_blank" rel="noopener">
                    <img style="border: none" class="lazyload" loading="lazy" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=140649f5-9394-46e8-bfe5-b4ea8a8c600e" alt="View Privacy Shield Verification Status" />
                </a>
                <a href="http://privacy.truste.com/privacy-seal/validation?rid=11c1aa82-b7e7-4a2f-b02e-ba935e661720" target="_blank" rel="noopener">
                    <img style="border: none" class="lazyload" loading="lazy" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=11c1aa82-b7e7-4a2f-b02e-ba935e661720" alt="View APEC CBPR Privacy Certification Status" />
                </a>
            </div>
        </div>
    </div>
</footer><!-- #footerMain -->
</div><!-- #page -->
<div id="fowardGuidanceModel" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3>Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA</h3>

            <div class="forward-guidance-content">
                <p>This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<br><br>

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.<br><br>

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).<br><br>

<b>No Duty to Update</b><br>

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

</p>            </div>

            <div class="btn-container text-center">
                <a href="../../index.html" class="btn tertiary">Decline</a>
                <a href="javascript:void()" class="btn tertiary negative" title="" onclick="sessionStorage.setItem('guidance-accepted', JSON.stringify(true)); document.getElementById('fowardGuidanceModel').style.display = 'none';">Accept</a>
            </div>

        </div>
    </div>
</div>
<link rel='stylesheet' id='related-content-styles-css'  href='../../wp-content/themes/mhh-merck-mco-theme/css/related-content-section.min9bd2.css?ver=5.9.4' media='all' />
<script defer="defer" src='../../wp-content/plugins/mhh-corporateberg/opt-in-communication-block/js/iframeResizer.min9bd2.js?ver=5.9.4' id='iframe-resize-js-js'></script>
<script defer="defer" src='../../wp-content/themes/mhh-merck-mco-theme/js/plugins.min367c.js?ver=20190301' id='Mco-plugins-js'></script>
<script defer="defer" src='../../wp-content/themes/mhh-merck-mco-theme/js/scripts.min367c.js?ver=20190301' id='Mco-scripts-js'></script>
<script defer="defer" src='../../wp-content/themes/mhh-merck-mco-theme/js/search_suggestions.minece0.js?ver=1664901626' id='search_suggestion-js'></script>
<div id="externalLinkModal" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3 id="externalLinkModalTitle">You are leaving Merck.com</h3>

            <div class="forward-guidance-content">
                <p id="externalLinkModalMessage" style="max-width: 31.25rem;"></p>
            </div>
            
            <div class="btn-container text-center">
                <button class="btn tertiary" id="externalLinkCancelBtn" title="" onclick="document.getElementById('externalLinkModal').style.display = 'none';">Cancel</button>
                <a href="#" target="_blank" class="btn tertiary negative" id="externalLinkModalBtn">Continue</a>
            </div>
        
        </div>
    </div>
</div>

<script type="text/javascript">
    let whitelist_domains =  ".local,merck-go-vip,merck-develop.go-vip.co/merck,merck-preprod.go-vip.co/merck,vip-msd.com/merck,merck.com,q4cdn.com,cloudfront.net,wpvip-safety-data-sheets.s3.amazonaws.com,google.com/calendar,outlook.live.com/calendar,calendar.yahoo.com,merckhelps.com,merckaccessprogram.com,merckmanuals.com,merckconnect.com,merckclinicaltrials.com,merck-animal-health.com,merckformothers.com,mrknewsroom.com,facebook.com,twitter.com,linkedin.com,mailto:,javascript:,tel:";
    let whitelist_domains_array = whitelist_domains.split(',');
    whitelist_domains_array.unshift(document.location.hostname);
        // External Links
    try {
        let links = Array.from(document.links);
        for (let i = 0; i < links.length; i++) {
            let link = links[i];
            if (!shouldWhitelistDomain(link.href)) {
                link.addEventListener("click", function (e) {
                    e.preventDefault();
                    let modal_data = getLinkContent(link.href);
                    document.getElementById('externalLinkModalTitle').textContent = modal_data.title;
                    document.getElementById('externalLinkModalMessage').textContent = modal_data.message;
                    document.getElementById('externalLinkModalBtn').href = this.href;
                    document.getElementById('externalLinkModalBtn').setAttribute('onclick', 'document.getElementById(\'externalLinkModal\').style.display = "none";');
                    document.getElementById('externalLinkModal').style.display = document.getElementById('externalLinkModal').style.display === 'none' ? 'block' : 'none';
                    
                    if (modal_data.cancelBtnText){
                        document.getElementById('externalLinkCancelBtn').textContent = modal_data.cancelBtnText;

                    }
                    if (modal_data.continueBtnText){
                        document.getElementById('externalLinkModalBtn').textContent = modal_data.continueBtnText;
                    }
                });
            }
        }
    } catch(ex) {
        console.log(ex);
    }

    function getLinkContent(link) {
        try {
            let title = htmlDecode("You are leaving Merck.com");
            let message = htmlDecode("The link you have selected will direct you to a site outside of www.merck.com. We are Merck &amp; Co. Inc., Rahway, NJ, USA known as MSD outside the United States and Canada. ");
            let cancelBtnText = htmlDecode("");
            let continueBtnText = htmlDecode("");
                        data = {
                title: title,
                message: message,
                cancelBtnText: cancelBtnText,
                continueBtnText: continueBtnText
            }
            return data;
        }
        catch(ex) {
            console.log(ex);
        }
    }

    function htmlDecode(input){
        if (input === '') return '';
        var e = document.createElement('div');
        e.innerHTML = input;
        return e.childNodes[0].nodeValue;
    }

    function shouldWhitelistDomain(link){
        return whitelist_domains_array.some(domain => new RegExp(domain).test(link));
    }
</script>
<div id="ukUserModal" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3>Welcome to Merck.com</h3>

            <div class="forward-guidance-content">
                <p style="max-width: 31.25rem;">By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.</p>
            </div>

            <div class="btn-container text-center">
                <a target="_blank" class="btn tertiary negative" id="externalLinkModalBtn" onclick="AcceptUKMessage();">Continue</a>
            </div>

        </div>
    </div>
</div>

<script type="text/javascript">
    function AcceptUKMessage() {
        try {
            let accepted = {
                expire: new Date(new Date().getTime() + 60 * 60 * 24 * 1000)
            };
            sessionStorage.setItem('uk-messaging', JSON.stringify(accepted));
            document.getElementById('ukUserModal').style.display = 'none';
        } catch (ex) {
            console.log(ex);
        }
    }
</script>

<script>console.log("US");</script><script>
		utag_data.page_datepublished = "2022-07-18 16:00:00";
	utag_data.page_datemodified = "2022-07-18 16:00:05";
	dataLayer.push(utag_data);
</script>

	<!-- OneTrust Cookies Consent Notice start -->
	<script src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"  type="text/javascript" charset="UTF-8" data-domain-script="fd658a96-8c4a-4c03-973e-fd83f98fa618"></script>
	<script type="text/javascript">
		function OptanonWrapper() { }
	</script>
	<!-- OneTrust Cookies Consent Notice end -->
	<script type="text/javascript">
                        /*
* FileSaver.js
* A saveAs() FileSaver implementation.
*
* By Eli Grey, http://eligrey.com
*
* License : https://github.com/eligrey/FileSaver.js/blob/master/LICENSE.md (MIT)
* source  : http://purl.eligrey.com/github/FileSaver.js
*/

// The one and only way of getting global scope in all environments
// https://stackoverflow.com/q/3277182/1008999
var _global = typeof window === 'object' && window.window === window
  ? window : typeof self === 'object' && self.self === self
  ? self : typeof global === 'object' && global.global === global
  ? global
  : this

function bom (blob, opts) {
  if (typeof opts === 'undefined') opts = { autoBom: false }
  else if (typeof opts !== 'object') {
    console.warn('Deprecated: Expected third argument to be a object')
    opts = { autoBom: !opts }
  }

  // prepend BOM for UTF-8 XML and text/* types (including HTML)
  // note: your browser will automatically convert UTF-16 U+FEFF to EF BB BF
  if (opts.autoBom && /^\s*(?:text\/\S*|application\/xml|\S*\/\S*\+xml)\s*;.*charset\s*=\s*utf-8/i.test(blob.type)) {
    return new Blob([String.fromCharCode(0xFEFF), blob], { type: blob.type })
  }
  return blob
}

function download (url, name, opts) {
  var xhr = new XMLHttpRequest()
  xhr.open('GET.html', url)
  xhr.responseType = 'blob'
  xhr.onload = function () {
    saveAs(xhr.response, name, opts)
  }
  xhr.onerror = function () {
    console.error('could not download file')
  }
  xhr.send()
}

function corsEnabled (url) {
  var xhr = new XMLHttpRequest()
  // use sync to avoid popup blocker
  xhr.open('HEAD.html', url, false)
  try {
    xhr.send()
  } catch (e) {}
  return xhr.status >= 200 && xhr.status <= 299
}

// `a.click()` doesn't work for all browsers (#465)
function click (node) {
  try {
    node.dispatchEvent(new MouseEvent('click'))
  } catch (e) {
    var evt = document.createEvent('MouseEvents')
    evt.initMouseEvent('click', true, true, window, 0, 0, 0, 80,
                          20, false, false, false, false, 0, null)
    node.dispatchEvent(evt)
  }
}

// Detect WebView inside a native macOS app by ruling out all browsers
// We just need to check for 'Safari' because all other browsers (besides Firefox) include that too
// https://www.whatismybrowser.com/guides/the-latest-user-agent/macos
var isMacOSWebView = /Macintosh/.test(navigator.userAgent) && /AppleWebKit/.test(navigator.userAgent) && !/Safari/.test(navigator.userAgent)

var saveAs = _global.saveAs || (
  // probably in some web worker
  (typeof window !== 'object' || window !== _global)
    ? function saveAs () { /* noop */ }

  // Use download attribute first if possible (#193 Lumia mobile) unless this is a macOS WebView
  : ('download' in HTMLAnchorElement.prototype && !isMacOSWebView)
  ? function saveAs (blob, name, opts) {
    var URL = _global.URL || _global.webkitURL
    var a = document.createElement('a')
    name = name || blob.name || 'download'

    a.download = name
    a.rel = 'noopener' // tabnabbing

    // TODO: detect chrome extensions & packaged apps
    // a.target = '_blank'

    if (typeof blob === 'string') {
      // Support regular links
      a.href = blob
      if (a.origin !== location.origin) {
        corsEnabled(a.href)
          ? download(blob, name, opts)
          : click(a, a.target = '_blank')
      } else {
        click(a)
      }
    } else {
      // Support blobs
      a.href = URL.createObjectURL(blob)
      setTimeout(function () { URL.revokeObjectURL(a.href) }, 4E4) // 40s
      setTimeout(function () { click(a) }, 0)
    }
  }

  // Use msSaveOrOpenBlob as a second approach
  : 'msSaveOrOpenBlob' in navigator
  ? function saveAs (blob, name, opts) {
    name = name || blob.name || 'download'

    if (typeof blob === 'string') {
      if (corsEnabled(blob)) {
        download(blob, name, opts)
      } else {
        var a = document.createElement('a')
        a.href = blob
        a.target = '_blank'
        setTimeout(function () { click(a) })
      }
    } else {
      navigator.msSaveOrOpenBlob(bom(blob, opts), name)
    }
  }

  // Fallback to using FileReader and a popup
  : function saveAs (blob, name, opts, popup) {
    // Open a popup immediately do go around popup blocker
    // Mostly only available on user interaction and the fileReader is async so...
    popup = popup || open('', '_blank')
    if (popup) {
      popup.document.title =
      popup.document.body.innerText = 'downloading...'
    }

    if (typeof blob === 'string') return download(blob, name, opts)

    var force = blob.type === 'application/octet-stream'
    var isSafari = /constructor/i.test(_global.HTMLElement) || _global.safari
    var isChromeIOS = /CriOS\/[\d]+/.test(navigator.userAgent)

    if ((isChromeIOS || (force && isSafari) || isMacOSWebView) && typeof FileReader !== 'undefined') {
      // Safari doesn't allow downloading of blob URLs
      var reader = new FileReader()
      reader.onloadend = function () {
        var url = reader.result
        url = isChromeIOS ? url : url.replace(/^data:[^;]*;/, 'data:attachment/file;')
        if (popup) popup.location.href = url
        else location = url
        popup = null // reverse-tabnabbing #460
      }
      reader.readAsDataURL(blob)
    } else {
      var URL = _global.URL || _global.webkitURL
      var url = URL.createObjectURL(blob)
      if (popup) popup.location = url
      else location.href = url
      popup = null // reverse-tabnabbing #460
      setTimeout(function () { URL.revokeObjectURL(url) }, 4E4) // 40s
    }
  }
)

_global.saveAs = saveAs.saveAs = saveAs

if (typeof module !== 'undefined') {
  module.exports = saveAs;
}

/*! ics.js Wed Sept 14 2017 */
var ics=function(e,t){"use strict";{if(!(navigator.userAgent.indexOf("MSIE")>-1&&-1==navigator.userAgent.indexOf("MSIE 10"))){void 0===e&&(e="default"),void 0===t&&(t="Calendar");var r=-1!==navigator.appVersion.indexOf("Win")?"\r\n":"\n",n=[],i=["BEGIN:VCALENDAR","PRODID:"+t,"VERSION:2.0"].join(r),o=r+"END:VCALENDAR",a=["SU","MO","TU","WE","TH","FR","SA"];return{events:function(){return n},calendar:function(){return i+r+n.join(r)+o},addEvent:function(t,i,o,l,u,s){if(void 0===t||void 0===i||void 0===o||void 0===l||void 0===u)return!1;if(s&&!s.rrule){if("YEARLY"!==s.freq&&"MONTHLY"!==s.freq&&"WEEKLY"!==s.freq&&"DAILY"!==s.freq)throw"Recurrence rrule frequency must be provided and be one of the following: 'YEARLY', 'MONTHLY', 'WEEKLY', or 'DAILY'";if(s.until&&isNaN(Date.parse(s.until)))throw"Recurrence rrule 'until' must be a valid date string";if(s.interval&&isNaN(parseInt(s.interval)))throw"Recurrence rrule 'interval' must be an integer";if(s.count&&isNaN(parseInt(s.count)))throw"Recurrence rrule 'count' must be an integer";if(void 0!==s.byday){if("[object Array]"!==Object.prototype.toString.call(s.byday))throw"Recurrence rrule 'byday' must be an array";if(s.byday.length>7)throw"Recurrence rrule 'byday' array must not be longer than the 7 days in a week";s.byday=s.byday.filter(function(e,t){return s.byday.indexOf(e)==t});for(var c in s.byday)if(a.indexOf(s.byday[c])<0)throw"Recurrence rrule 'byday' values must include only the following: 'SU', 'MO', 'TU', 'WE', 'TH', 'FR', 'SA'"}}var g=new Date(l),d=new Date(u),f=new Date,S=("0000"+g.getFullYear().toString()).slice(-4),E=("00"+(g.getMonth()+1).toString()).slice(-2),v=("00"+g.getDate().toString()).slice(-2),y=("00"+g.getHours().toString()).slice(-2),A=("00"+g.getMinutes().toString()).slice(-2),T=("00"+g.getSeconds().toString()).slice(-2),b=("0000"+d.getFullYear().toString()).slice(-4),D=("00"+(d.getMonth()+1).toString()).slice(-2),N=("00"+d.getDate().toString()).slice(-2),h=("00"+d.getHours().toString()).slice(-2),I=("00"+d.getMinutes().toString()).slice(-2),R=("00"+d.getMinutes().toString()).slice(-2),M=("0000"+f.getFullYear().toString()).slice(-4),w=("00"+(f.getMonth()+1).toString()).slice(-2),L=("00"+f.getDate().toString()).slice(-2),O=("00"+f.getHours().toString()).slice(-2),p=("00"+f.getMinutes().toString()).slice(-2),Y=("00"+f.getMinutes().toString()).slice(-2),U="",V="";y+A+T+h+I+R!=0&&(U="T"+y+A+T,V="T"+h+I+R);var B,C=S+E+v+U,j=b+D+N+V,m=M+w+L+("T"+O+p+Y);if(s)if(s.rrule)B=s.rrule;else{if(B="rrule:FREQ="+s.freq,s.until){var x=new Date(Date.parse(s.until)).toISOString();B+=";UNTIL="+x.substring(0,x.length-13).replace(/[-]/g,"")+"000000Z"}s.interval&&(B+=";INTERVAL="+s.interval),s.count&&(B+=";COUNT="+s.count),s.byday&&s.byday.length>0&&(B+=";BYDAY="+s.byday.join(","))}(new Date).toISOString();var H=["BEGIN:VEVENT","UID:"+n.length+"@"+e,"CLASS:PUBLIC","DESCRIPTION:"+i,"DTSTAMP;VALUE=DATE-TIME:"+m,"DTSTART;VALUE=DATE-TIME:"+C,"DTEND;VALUE=DATE-TIME:"+j,"LOCATION:"+o,"SUMMARY;LANGUAGE=en-us:"+t,"TRANSP:TRANSPARENT","END:VEVENT"];return B&&H.splice(4,0,B),H=H.join(r),n.push(H),H},download:function(e,t){if(n.length<1)return!1;t=void 0!==t?t:".ics",e=void 0!==e?e:"calendar";var a,l=i+r+n.join(r)+o;if(-1===navigator.userAgent.indexOf("MSIE 10"))a=new Blob([l]);else{var u=new BlobBuilder;u.append(l),a=u.getBlob("text/x-vCalendar;charset="+document.characterSet)}return saveAs(a,e+t),l},build:function(){return!(n.length<1)&&i+r+n.join(r)+o}}}console.log("Unsupported Browser")}};


function GenerateICS(title, description, start, end) {
    let cal = new ics();
    cal.addEvent(decodeURIComponent(title), decodeURIComponent(description), "", start, end);
    cal.download(decodeURIComponent(title));
}
</script><script>
    /* https://stackoverflow.com/a/26633844/3019650 */
    if (!window.CSS || !CSS.supports('color', 'var(--fake-var)')) {
        (function(a, b, c, d) {
            a = 'https://cdn.jsdelivr.net/npm/css-vars-ponyfill@2';
            b = document;
            c = 'script';
            d = b.createElement(c);
            d.src = a;
            d.type = 'text/java' + c;
            d.async = true;
            a = b.getElementsByTagName(c)[0];
            a.parentNode.insertBefore(d, a);
        })();

        function deferCssVars(method) {
            if (typeof cssVars === "function") {
                method();
            } else {
                setTimeout(function() {
                    deferCssVars(method)
                }, 50);
            }
        }
        deferCssVars(function() {
            cssVars()
        });
    }
</script>
</body>


<!-- Mirrored from www.merck.com/news/lynk-003-trial-evaluating-lynparza-olaparib-with-or-without-bevacizumab-in-patients-with-unresectable-or-metastatic-colorectal-cancer-to-stop-for-futility/ by HTTrack Website Copier/3.x [XR&CO'2014], Tue, 04 Oct 2022 17:18:39 GMT -->
</html>
